Nestlé
Search results
At Galderma, we embrace these differences and offer cutting-edge, premium brands that fit people's individual needs, across the full spectrum of dermatology through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Galderma S.A. is an American-Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé , it has been held by a consortium of private institutional investors since 2019.
Galderma is the pure-play dermatology category leader, committed to advancing dermatology for every skin story. Leveraging our unique 40-year heritage of leading science-based innovation, we deliver a synergistic portfolio of flagship brands and services that span the full spectrum of dermatology.
We offer a synergistic portfolio of flagship brands with leading market positions in their respective product categories, supported by science-based product differentiation and premium positioning. Our innovative product range includes the following sophisticated brands: Close.
Galderma is a focused dermatology company which started in 1981. Galderma is committed to the healthcare community by partnering with healthcare professionals. We provide prescription drugs and aesthetic solutions and go beyond treating skin problems by delivering safe and efficient quality treatments to meet the skin health needs of people ...
Discover the exclusive aesthetics portfolio of dermal fillers, toxins, the original skinbooster and the original collagen biostimulator from Galderma.
Galderma | 357,332 followers on LinkedIn. We are advancing dermatology for every skin story | Galderma is the leading company solely dedicated to skin and advancing the future of dermatology.
Mar 6, 2024 · One of the world’s largest dermatology companies is aiming to raise $2.3bn in an initial public offering on the Swiss stock exchange, in the latest sign that Europe’s listings markets is ...
Apr 24, 2024 · The Investor Relations website contains information about Galderma's business for stockholders, potential investors, and financial analysts.
Aug 25, 2022 · Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD. Particularly strong performance of Injectable...
